| Company Name: |
Phygene Gold |
| Tel: |
18059081430 |
| Email: |
2070812664@qq.com |
Glepaglutide manufacturers
- Glepaglutide
-
- $70.00
-
2026-08-25
- CAS:914009-86-2
- Min. Order: 10kg
- Purity: 0.99
- Supply Ability: 20tons
|
| | Glepaglutide Basic information |
| | Glepaglutide Chemical Properties |
| Sequence | H-His-Gly-Glu-Gly-Thr-Phe-Ser-Ser-Glu-Leu-Ala-Thr-Ile-Leu-Asp-Ala-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Ala-Trp-Leu-Ile-Ala-Thr-Lys-Ile-Thr-Asp-Lys-Lys-Lys-Lys-Lys-Lys-NH2 |
| | Glepaglutide Usage And Synthesis |
| Uses | Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease[1][2][3]. | | in vivo | Glepaglutide (200 and 400 nmol/kg, s.c., twice a day for 14 days) shows intestinotrophic effect in rats with small intestinal inflammation[3].
| Animal Model: | Rats with Indomethacin (HY-14397)-induced small intestinal inflammation[3] | | Dosage: | 200 and 400 nmol/kg | | Administration: | Subcutaneousinjection (s.c.), twice a day for 14 days. | | Result: | Increased plasma citrulline concentration.
Increased small intestinal mass.
Decreased small intestinal concentrations of the inflammatory marker (AGP and MPO).
|
| | References | [1] Naimi RM, et al. a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2019 May;4(5):354-363. DOI:10.1016/S2468-1253(19)30077-9
[2] Janssen P, et al. Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther. 2013 Jan;37(1):18-36. DOI:10.1111/apt.12092
[3] Jolanta Skarbaliene, et al. ZP1848, a Novel GLP-2 Agonist, Provides a Wide Window of Therapeutic Efficacy in the Experimental Crohn's Disease Model. Gastroenterology, 2011, 140(5): S519. |
| | Glepaglutide Preparation Products And Raw materials |
|